@article{TLCR421,
author = {Hui Gao and Xin Ding and Dong Wei and Peng Cheng and Xiaomei Su and Huanyi Liu and Fahad Aziz and Daoyuan Wang and Tao Zhang},
title = {Erlotinib in patients with advanced non-small-cell lung cancer: A meta-analysis},
journal = {Translational Lung Cancer Research},
volume = {1},
number = {2},
year = {2012},
keywords = {},
abstract = {Erlotinib is a potent reversible HER1/epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with single-agent activity in patients with non–small-cell lung cancer (NSCLC). In this article, we updated the evidence of erlotinib in treating advanced NSCLC by adding new results of RCTs published between January 2011 and May 2012 into a pooled analysis which had been published in 2011. Outcomes analyzed were objective response rate (ORR), progression free survival (PFS), overall survival (OS) and adverse events. Twenty trials including 9,005 patients were identified, and six of them were recently published. As first-line therapy compared to placebo or chemotherapy, there was a similar ORR (P=0.29 and 0.42), PFS (P=0.09 and 0.25) and OS (P=0.73 and 0.49). However, for the patients with EGFR mutations, erlotinib based regimens could significantly improve ORR (P},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/421}
}